Suppr超能文献

炎症性肠病中的m6A修饰为临床应用提供了新见解。

m6A modification in inflammatory bowel disease provides new insights into clinical applications.

作者信息

Zhang Jiamin, Song Bimei, Zeng Yue, Xu Chao, Gao Liang, Guo Yan, Liu Jingbo

机构信息

Department of Periodontics, School of Stomatology, China Medical University, 117 Nanjing North Street, Shenyang 110002, China.

Department of Central Laboratory, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Disease, Shenyang 110002, China; Department of Oral Biology, School and Hospital of Stomatology, China Medical University, Liaoning Provincial Key Laboratory of Oral Disease, Shenyang 110002, China.

出版信息

Biomed Pharmacother. 2023 Mar;159:114298. doi: 10.1016/j.biopha.2023.114298. Epub 2023 Jan 25.

Abstract

Inflammatory bowel disease (IBD) results from a complex interplay between genetic predisposition, environmental factors, and gut microbes. The role of N6-methyladenosine (m6A) methylation in the pathogenesis of IBD has attracted increasing attention. m6A modification not only regulates intestinal mucosal immunity and intestinal barrier function, but also affects apoptosis and autophagy in intestinal epithelial cells. Additionally, m6A modification participated in the interaction between gut microbes and the host, providing a novel direction to explore the molecular mechanisms of IBD and the theoretical basis for specific microorganism-oriented prevention and treatment measures. m6A regulators are expected to be biomarkers for predicting the prognosis of IBD patients. m6A methylation may be utilized as a novel target in the management of IBD. This review focused on the recent advances in how m6A modification causes the initiation and development of IBD, and provided new insights into optimal prevention and treatment measures for IBD.

摘要

炎症性肠病(IBD)是由遗传易感性、环境因素和肠道微生物之间复杂的相互作用引起的。N6-甲基腺苷(m6A)甲基化在IBD发病机制中的作用已引起越来越多的关注。m6A修饰不仅调节肠道黏膜免疫和肠道屏障功能,还影响肠道上皮细胞的凋亡和自噬。此外,m6A修饰参与了肠道微生物与宿主之间的相互作用,为探索IBD的分子机制提供了新方向,并为以特定微生物为导向的预防和治疗措施提供了理论基础。m6A调节剂有望成为预测IBD患者预后的生物标志物。m6A甲基化可能被用作IBD治疗的新靶点。本综述重点关注m6A修饰导致IBD发生和发展的最新进展,并为IBD的最佳预防和治疗措施提供新见解。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验